Qatar Metabolomics Study on Diabetes

The Qatar Metabolomics Study on Diabetes (QMDiab) is a type 2 diabetes case-control, which was conducted in 2012 at the Dermatology Department of Hamad Medical Corporation and the Weill Cornell Medical College in Doha, Qatar. The study was approved by the Institutional Review Boards of HMC and WCM-Q under research protocol number 11131/11. All study participants provided written informed consent.<br><br>Untargeted metabolomics measurements (LC/MS+, LC/MS-, and GC/MS) from plasma, urine, and saliva samples of 374 participants, which are aged 17-81 years, were performed by Metabolon Inc.<br><br>The OrigScale dataset comprises median-scaled data for each body fluid. The Preprocessed dataset comprises missing values treated, normalized, transformed, and scaled data. In both datasets, rows correspond to participants (anonymized) and columns correspond to metabolites. <br><br>Phenotype information (type 2 diabetes status, age, gender, BMI, ethnicity) are available as the last six columns of each dataset.<br>Annotations and pathway assigments are also provided for each metabolite.

卡塔尔糖尿病代谢组学研究（Qatar Metabolomics Study on Diabetes, QMDiab）是一项2型糖尿病病例对照研究，于2012年在卡塔尔多哈的哈马德医疗公司（Hamad Medical Corporation, HMC）皮肤科及威尔康奈尔医学院开展。本研究已通过HMC与卡塔尔威尔康奈尔医学院（Weill Cornell Medical College in Qatar, WCM-Q）的机构审查委员会批准，研究编号为11131/11。所有研究参与者均签署了书面知情同意书。<br><br>本研究共纳入374名年龄介于17至81岁的参与者，由Metabolon公司对其血浆、尿液及唾液样本开展非靶向代谢组学检测，检测模式涵盖LC/MS+、LC/MS-及GC/MS。<br><br>OrigScale数据集包含针对每种体液的中位数缩放数据；Preprocessed数据集则为经过缺失值处理、标准化、转换及缩放操作后的数据集。两类数据集均以行代表已匿名化的参与者，列代表代谢物。<br><br>两类数据集的最后六列均包含表型信息，包括2型糖尿病患病状态、年龄、性别、身体质量指数（Body Mass Index, BMI）及种族。此外，还为每个代谢物提供了注释信息及通路分配结果。

搜集汇总

背景与挑战

背景概述

该数据集是卡塔尔2型糖尿病病例对照研究的代谢组学数据，包含374名参与者的血浆、尿液和唾液样本的非靶向代谢组学测量数据，以及相关的表型信息和代谢物注释。数据集提供原始尺度和预处理两种形式的数据，适用于代谢组学分析和糖尿病研究。